SCHEMBL3529403

SCHEMBL3529403

CS(=O)(=O)Nc1cccc(C(=O)O)c1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.55
CCR2 P41597 1/20 0.52
MEN1 O00255 4/20 0.50
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
TSHR P16473 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PDK1 Q15118 1/20 0.50
PDK2 Q15119 1/20 0.50
PDK3 Q15120 1/20 0.50
PDK4 Q16654 1/20 0.50
MCL1 Q07820 1/20 0.49
MMP2 P08253 1/20 0.49
RCE1 Q9Y256 1/20 0.48
HSD17B10 Q99714 1/20 0.48
KEAP1 Q14145 2/20 0.46
NFE2L2 Q16236 1/20 0.46
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13602477 0.87 ALDH1A1 (0.54) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL3527090 0.84 TSHR (0.61) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL13747186 0.83 KDM4E (0.48) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL13719491 0.83 KMT2A (0.48) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL220059 0.82 KMT2A (0.72) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL13690065 0.82 KMT2A (0.46) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL3789124 0.82 KEAP1 (0.59) KMT2AMEN1KDM4EALDH1A1HPGD
SCHEMBL13823614 0.81 KMT2A (0.57) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL27396813 0.81 KMT2A (0.57) KMT2ACCR2MEN1KDM4EALDH1A1
SCHEMBL5226243 0.81 KEAP1 (0.61) KMT2ACCR2MEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 KMT2A 4565/4885CCR2 4/4885MEN1 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.